Zenith Drugs Confirms Zero Deviation in Preferential Issue Funds Utilization
Zenith Drugs Ltd · Others (Uncategorized) · 14 Nov 2026, 9:17 pm
Zenith Drugs Confirms Zero Deviation in Preferential Issue Funds Utilization Zenith Drugs Limited reported no deviation or variation in the utilization of preferential issue proceeds for the half-year ended 30th Sep'26. On 26th Aug'26, the company allotted 16,09,050 convertible warrants to promoters at ₹43.50 per warrant. The company received upfront subscription proceeds of ₹1.75 crore (25% of total consideration at ₹10.88 per warrant), which were fully deployed toward working capital requirements. The remaining 75% exercise price of ₹32.62 per warrant is payable upon equity conversion within an 18-month timeframe.
Original exchange filing (PDF)
More announcements from Zenith Drugs Ltd
- Zenith Drugs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 14 Nov 2026
- Zenith Drugs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 14 Nov 2026
- Zenith Drugs Limited has informed the Exchange about Board Meeting to be held on 14-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . · 14 Nov 2026
- To consider and approve the financial results for the period ended September 30, 2026 · 14 Nov 2026
- Zenith Drugs Limited has informed the Exchange about securing a tender awarded Rajasthan Medical Services Corporation Limited. · 04 Nov 2026
- Zenith Drugs Limited has informed the Exchange about securing a tender awarded by Uttar Pradesh Medical Supplies Corporation Limited. · 30 Oct 2026
- Zenith Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on October 13, 2026. · 13 Oct 2026
- Zenith Drugs Limited has informed the Exchange about securing a tender awarded by Haryana Medical Services Corporation Limited. · 10 Oct 2026
